NCI-2025-00167

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for CommonEGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This Phase 2b research study is testing a new, faster way to give the cancer drug amivantamab as a subcutaneous (under-the-skin) injection instead of the usual IV infusion for people with EGFR-mutated non-small cell lung cancer (NSCLC). The study has two groups: one where newly diagnosed patients receive amivantamab plus lazertinib as first-line treatment, and another where patients who’ve already been treated receive amivantamab plus platinum-based chemotherapy. Researchers want to see if the injection is as effective, safe, and more convenient than the traditional IV version—offering shorter treatment times, fewer side effects, and an improved experience for patients.

EGFR: Epidermal Growth Factor Receptor (EGFR) is on the surface of cells and helps them grow and divide. In cancer, EGFR is like a switch that gets stuck in the "on" position, making cells grow and divide too much.

Non-small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06667076

Clinical Trial Site: Columbia

To see all available clinical trials click here.